risedronic acid has been researched along with Heart Disease, Ischemic in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Excerpt | Relevance | Reference |
---|---|---|
"Comorbid factors such as ischemic heart disease, hip osteoarthritis, and higher values of FRAX blunted the effects of QOL of the treatment." | 1.38 | The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study. ( Hayakawa, Y; Iinuma, N; Itoh, M; Iwayama, S; Kamisaki, T; Nakamura, T; Nishikawa, M; Osawa, M; Suzuki, H; Yamaguchi, H, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Nakamura, T | 1 |
Osawa, M | 1 |
Itoh, M | 1 |
Yamaguchi, H | 1 |
Iinuma, N | 1 |
Hayakawa, Y | 1 |
Suzuki, H | 1 |
Kamisaki, T | 1 |
Iwayama, S | 1 |
Nishikawa, M | 1 |
1 other study available for risedronic acid and Heart Disease, Ischemic
Article | Year |
---|---|
The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Bone Density Conservation Agents; Comorbidity; | 2012 |